2021, Number 1
<< Back Next >>
Rev Cubana Invest Bioméd 2021; 40 (1)
Clinical characterization of urinary tract infections caused by extended-spectrum betalactamase producing enterobacteria
Navarrete MPJ, Loayza AMJ, Velasco GJC, Benites AJC
Language: Spanish
References: 19
Page: 1-11
PDF size: 372.99 Kb.
ABSTRACT
Introduction:
Urinary tract infections are among the most prevalent infections in clinical practice. They are a global health problem and may present with or without symptoms. The bacterial agents most commonly isolated are Escherichia coli, Klebsiella spp. and Proteus spp.
Objective:
Characterize urinary tract infections caused by extended-spectrum betalactamase producing enterobacteria in hospitalized patients from Lima in the period 2016-2018.
Methods:
A descriptive study was conducted at two health institutions from Lima, Peru, in the period 2016-2018, based on isolation of ESBL pathogens associated to urinary tract infections. Attention was paid to sociodemographic variables, associated conditions, agents isolated, treatment and clinical response.
Results:
A sample was selected of 117 patients; mean age was 58.18 ± 11.8 years; 65.0% were women and 89.74% came from the urban area of Lima. The most common associated conditions were diabetes (39.3%) and moderate or serious kidney disease (12.8%), with a mean Charlson index of 2.70 ± 1.21. The most common isolated agents were Escherichia coli (92.3%), Klebsiella spp. (6.0%) and Proteus spp. (1.7%). The empirical treatments used were ampicillin/sulbactam (18.9%), ciprofloxacin (49.6%) and nitrofurantoin (16.7%). 49.2% of the patients received targeted treatment, 22.8% ertapenem and 13.9% piperacillin/tazobactam.
Conclusions:
People with diabetes and kidney disease are vulnerable to urinary tract infections. The causative agent most commonly isolated was ESBL Escherichia coli. The initial treatments indicated after clinical identification of urinary infection were ciprofloxacin and cephalosporins. When microbiological results were obtained, antibiotic therapy was changed to carbapenems and penicillins. Reassessment of the antibiotics used in patients with associated conditions is important for the success of the treatment.
REFERENCES
Guevara N, Guzmán M, Merentes A, Rizzi A, Papaptzikos J, Rivero N, et al. Patrones de susceptibilidad antimicrobiana de bacterias gramnegativos aisladas de infecciones del tracto urinario en Venezuela: Resultados del estudio SMART 2009-2012. Revista Chilena de Infectología. 2015;32(6):639-48.
Echevarría J, Sarmiento E, Osores F. Infección del tracto urinario y manejo antibiótico. Acta méd peruana. 2006;23(1):26-31.
Avilés C, Betancour P, Velasco C, Godoy R, Barthel E, Martínez F. Factores asociados a infecciones urinarias producidas por enterobacterias productoras de ß-lactamasas de espectro extendido: una cohorte prospectiva. Revista Chilena de Infectología. 2016;33(6):628-34.
Galindo M. Caracterización molecular y patrón de susceptibilidad antimicrobiana de Escherichia coli productora de ß-lactamasas de espectro extendido en infección del tracto urinario adquirida en la comunidad. Revista Chilena de Infectología. 2018;35(1):29-35.
Silva L, Sosa O, García J. Características y factores de riesgo de la infección de vías urinarias con cultivo positivo para betalactamasas de espectro extendido en adultos atendidos en urgencias en el Hospital Militar Central. Infectio. 2018;22(3):147-52.
García M. Escherichia coli portador de betalactamasas de espectro extendido: resistencia. Sanid Mil. 2013;69(4):244-8.
Hernández E, Araque M, Millán Y, Millán B, Vielma S. Prevalencia de ß-lactamasa CTX-M-15 en grupos filogenéticos de Escherichia coli uropatógena aisladas en pacientes de la comunidad en Mérida, Venezuela. Invest Clin. 2014;55(1):32-43.
Zúniga J, Bejarano S, Valenzuela H, Gough S, Castro A, Chinchilla C, et al. Perfil de sensibilidad a los antibióticos de las bacterias en infecciones del tracto urinario. Acta méd costarric. 2016;58(4):146-54.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 2003;40(5):373-83.
Leal A, Cortés J, Arias G, Ovalle M, Saavedra S, Buitrago G, et al. Emergencia de fenotipos resistentes a cefalosporinas de tercera generación en Enterobacteriaceae causantes de infección del tracto urinario de inicio comunitario en hospitales de Colombia. Enferm Infecc Microbiol Clin. 2013;31(5):298-303.
Escalante-Montoya J, Síme-Díaz A, Díaz-Vélez C. Clinical and epidemiological characteristics of patients with nosocomial infection by bacteria producing extended spectrum beta-lactamase. Revista Peruana de Epidemiología. 2013;17(1):1-6.
Diestra K, Coque T, Miró E, Oteo J, Nicolau C, Campos J, Moya B, et al. Caracterización y epidemiología molecular de betalactamasas de espectro extendido en Escherichia coli y Klebsiella pneumoniae en once hospitales españoles. Enferm Infecc Microbiol Clin. 2008;26(7):404-10.
Briongos LS, Gómez T, Bachiller P, Domínguez M, Gómez A, Palacios T, et al. Epidemiology, risk factors and comorbidity for urinary tract infections caused by extendedspectrum betalactamase (ESBL) - producing enterobacteria. NT J Clin Pract. 2012;66(9):891-6.
Hernández JR, Pascual A, Cantón R, Martínez L. Escherichia coli y Klebsiella pneumoniae productoras de betalactamasas de espectro extendido en hospitales españoles (Proyecto GEIH-BLEE 2000). Enferm Infecc Microbiol Clin. 2003;21:77-82.
Schoevaerdts D, Bogaerts P, Grimmelprez A, De Saint-Hubert M, Delaere B, Jamart J, et al. Clinical profiles of patients colonized or infected with extended-spectrum betalactamase producing enterobacteriaceae isolates: A 20 month retrospective study at a Belgian University Hospital. BMC Infect Dis. 2010;12:1-12.
Philippon A, Arlet G, Lagrange PH. Origin and impact of plasmid-mediated extended spectrum beta-lactamases. Eur J Clin Microbiol Infect Dis. 1994;13(Suppl 1):S17-S29.
Castro-Orozco R, Barreto-Maya AC, Guzmán-Álvarez H, Ortega-Quiroz RJ, Benítez-Peña L. Patrones de resistencia antimicrobiana en uropatógenos gramnegativos aislados de pacientes ambulatorios y hospitalizados Cartagena, 2005-2008. Rev Salud Pública. 2010;12(6):1010-9.
Gómez C, Plata M, Sejnaui J, Rico C, Vanegas B. Resistencia de la E. coli en urocultivos de pacientes con sospecha de infección urinaria intra y extra hospitalaria en la Fundación Santa Fe de Bogotá. Urología Colombiana. 2009;18(1):53-8.
Wu UI, Yang CS, Chen WC, Chen YC, Chang SC. Risk factors for bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli. J Microbiol Inmunol Infect. 2010;43(4):310-16.